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Abstract
A novel role of the dihydroorotatedehydrogenase (DHODH) inhibitor leflunomide as a potential anti-melanoma therapy was
recently reported (Nature 471:518-22, 2011). We previously reported that leflunomide strongly activates the transcriptional
activity of the Aryl Hydrocarbon Receptor (AhR). We therefore tested whether the AhR regulates the anti-proliferative effects
of leflunomide in melanoma. We first evaluated the expression of AhR in melanoma cells and found that AhR is highly
expressed in A375 melanoma as well as in several other cancer cell types. To evaluate whether AhR plays a role in regulating
the growth inhibitory effects of leflunomide in A375 cells, we generated a stable cell line from parental A375 cells
expressing a doxycycline (DOX) inducible AhR shRNA. Using these cells in the absence or presence of DOX (normal AhR
levels or AhR-knockdown, respectively) we found that the anti-proliferative effects of leflunomide, but not its metabolite
A771726, were strongly dependent upon AhR expression. It has been well established that supplementation of cells with
exogenous uridine completely rescues the anti-proliferative effects due to DHODH inhibition. Thus, we performed uridine
rescue experiments in A375 cells to determine whether the anti-proliferative effects of leflunomide are solely due to DHODH
inhibition as previously reported. Interestingly, saturating levels of uridine only modestly rescued A375 cells from the anti-
proliferative effects of both leflunomide and A771726, indicating additional mechanism(s), apart from DHODH inhibition are
responsible for the anti-proliferative effects of leflunomide in melanoma cells. Uridine also did not rescue MDA-MB-435S
melanoma cell proliferation after leflunomide treatment. Our results reveal that the AhR is a molecular target of leflunomide
and support the feasibility of the clinical application of leflunomide for treating melanoma. Furthermore, analysis of
expression data from 967 cancer cell lines revealed that AhR is expressed in multiple different cancer types supporting the
intriguing possibility of targeting the AhR for therapy in a number of cancers.
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Introduction
The Aryl Hydrocarbon Receptor (AhR) is a ligand activated
transcription factor belonging to the basic helix-loop-helix PER/
ARNT/SIM (bHLH/PAS) family of transcription factors and
regulates a wide range of biological activities ranging from
transcriptional modulation of a battery of genes involved in
xenobiotic metabolism, most notably members of the cytochrome
P450 family, to cell cycle progression through both ligand
dependent and independent mechanisms. [1–7] The AhR is
localized in the cytosol, and upon activation by a ligand
translocates to the nucleus where it binds its obligate heterodimeric
partner AhR Nuclear Translocator protein (ARNT). This complex
proceeds to bind AhR/xenobiotic response elements to regulate
the transcription of a battery of target genes in a ligand dependent
manner.
A novel and clinically important role for the AhR as a target for
anti-cancer therapies has emerged from its classically studied role
as a mediator of the effects of environmental toxins such as 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). Recently, the AhR has been
shown to act as a tumor suppressor in a mouse model of prostate
cancer. [8,9] Selective AhR modulators that interfere with
estrogen receptor transcription have been shown to inhibit breast
cancer cell proliferation. [10–12] The AhR has also been shown to
suppress diethylnitrosamine (DEN) induced liver cancers in the
absence of exogenous ligands, [13] and the Aryl Hydrocarbon
Receptor Repressor, itself an AhR-target gene, has been shown to
mediate tumor suppression in tissues derived from multiple human
cancers including those of the colon, breast, lung, stomach, cervix,
and ovaries. [14] At the cellular level, the AhR can inhibit
proliferation through several distinct mechanisms. [5,15] In
a ligand and cell-type specific manner, activation of the AhR
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Kip1 and p21
Cip1.
[2,16] The AhR has also been shown to interact with retinoblas-
toma protein to induce cell cycle arrest by enhancing repression of
E2F-dependent transcription. [4]
A few FDA approved drugs have recently been shown to
activate AhR transcription. [17–19] For example, we recently
reported that AhR activation by leflunomide, a well known
immunosuppressive agent used to treat rheumatoid arthritis, alters
cell proliferation and tissue regeneration in a context-specific
manner. [18,20] Leflunomide is converted to its primary
metabolite A771726 via isoxazole ring cleavage, and whereas
metabolism of leflunomide to A771726 is required for dihydroor-
otatedehydrogenase (DHODH) inhibition, [21] this conversion
significantly abrogates the AhR-activating properties of lefluno-
mide. [18]
Recently, White et al. reported that DHODH modulates
transcriptional elongation in melanoma, and that inhibition of
DHODH by leflunomide may be an effective anti-melanoma
therapy. [22] Development of new therapeutic approaches for the
treatment of melanoma is important, as melanoma accounts for
approximately 75% of all skin-cancer related deaths. [23]
Interestingly, expression of AhR has been observed in both
primary human melanocytes as well as FM55 melanoma cells, in
which the endogenously produced tryptophan metabolite 6-
formylindolo[3,2-b]carbazole (FICZ) has been demonstrated as
a putative AhR ligand capable of regulating melanogenesis in an
AhR-dependent manner. [24,25] The study by White et al.
prompted us to test whether the AhR has a role in regulating the
effects of leflunomide in melanoma. [22] Our results revealed that
the AhR is essential in mediating the anti-proliferative effects of
leflunomide in melanoma cells and that the inhibition of DHODH
by leflunomide’s active metabolite A771726 can only partially
account for inhibition of melanoma cells. Analysis of expression
data from 967 cancer cells revealed that AhR is broadly expressed
in several cancer types including lung, breast, liver, stomach and
pancreas. [26]
Materials and Methods
Cell Culture
Maintenance of HEK293T cells and WT Hepa1c1c7 cells
(herein Hepa1) in our laboratory has been described previously.
[18,27,28] HEK293T, MDA-MB-435S, Hepa1, and A375 cells
were purchased from American Type Culture Collection (ATCC,
Manassas, VA). Cells were cultured in Dulbecco’s Modified Eagle
Medium with L-glutamine (Mediatech Inc., Manassas, VA)
supplemented with 10% FBS (Tissue Culture Biologicals, Tulare,
CA), 100 U/mL penicillin, and 100 mg/mL streptomycin (Med-
iatech Inc., Manassas, VA) at 37uC with in a humidified 5% CO2
atmosphere. Cells were routinely passaged at a dilution of 1:5
every 2–3 days.
Chemicals & Reagents
Preparation of leflunomide and A771726 was as previously
described. [18] Briefly, both compounds were dissolved in DMSO
to a final concentration of 100 mM. All other chemicals and
reagents were purchased from Sigma (St Louis, MO) unless
otherwise indicated. The final concentration of DMSO was 0.1%
v/v in all cell culture assays.
Inducible AhR Knockdown in A375 Cells
293T cells in 15 cm dishes at ,60% confluence were co-
transfected by calcium phosphate precipitation with 20 mgo f
a pTRIPZ vector (Openbiosystems, Thermo Scientific) expressing
an shRNA against AhR (sense, 59-CGGGCTCTTTCAAGA-
TAGTAAA939), 20 mg of the packaging vector psPAX2, and
10 mg of the envelope vector pMD2.G (Addgene). Media was
replaced 24 hours after transfection, and supernatants containing
lentivirus particles were collected after a further 24 hours and
applied to A375 cells with 8 mg/mL polybrene (Sigma). 24 hours
later, cell medium was exchanged with fresh medium containing
3 mg/mL of puromycin to select transduced cells. Non-infected
cells were included as a control for puromycin toxicity, and only
after 100% of the cells had perished was the selection process
considered complete. In addition, stable cell lines were maintained
in puromycin until sufficient freezer stocks were generated. Cells
were maintained in puromycin for at least one week after thawing.
BSL-2 protocols were used for the handling of all virus particles
and infections. The final generated cells, A375-pTRIPZ-shAhR,
were cultured as described above for A375 cells, except that for
AhR knockdown experiments, media containing 2 mg/mL doxy-
cycline (DOX) was exchanged every other day. Non-induced (i.e.
no-DOX) cells were maintained as controls. Expression of RFP
throughout knockdown experiments was routinely confirmed by
either fluorescence microscopy or flow cytometry, while AhR
knockdown status at the beginning and end of experiments was
routinely verified by Western blot.
Western Blotting
Analysis of protein abundance was performed by Western blot
according to standard techniques. Briefly, cells were collected by
trypsinization, resuspended in 1 volume of PBS, lysed in an equal
volume of 2X Laemmli Sample Buffer, boiled for 5 min, and
stored at 280uC until needed. Lysates were subjected to SDS-
PAGE on 4–12% pre-cast XT-Criterion gradient gels (Biorad,
Hercules, CA) and transferred to PVDF membranes by semi-dry
transfer. Afterwards, blots were blocked in 5% TBSTM and
incubated overnight at 4uC with primary antibodies. Primary
antibodies were as follows: rabbit-anti-AhR was from Enzo Life
Sciences (Farmingdale, NY) and mouse-anti-GAPDH was from
SCBT (Santa Cruz, CA); all other antibodies (mouse anti-CDK6,
mouse anti-CDK4, mouse-anti-p21, mouse-anti-p27, mouse-anti-
Cyclin-D1, and mouse-anti-Cyclin-D3) were purchased from Cell
Signaling Technology (Danvers, MA). After incubation with
primary antibodies, blots were washed with 0.1% TBST three
times for 5 minutes each, followed by incubation at room
temperature with goat-anti-mouse or goat-anti-rabbit antibodies
(Southern Biotech, Birmingham, AL) conjugated with HRP in 5%
TBSTM. Washing was repeated as above, and blots were
visualized with SuperSignal West Pico chemiluminescent agent
(Pierce Biotechnology/Thermo Scientific, Rockford, IL) using
a ChemiGenius Bio Imaging System and Gene Snap Software
(Synoptics LTD, Cambridge, UK).
Gene Expression Analysis
Collection of total RNA and reverse transcription reactions
were performed exactly as described previously. [18,27] Quanti-
tative Polymerase Chain Reaction (qPCR) analysis was performed
using an ABI7500 Fast Real-Time PCR system (ABI, Foster city,
CA) with RT
2 Real-Time
TM SYBR Green/Rox PCR master mix
(SA Biosciences/Qiagen, Frederick, MD) according to the
manufactures recommended protocol. Briefly, 25 mL reactions
(12.5 mL 2X master mix, 1 mL cDNA, 1 mL 10 mM forward &
reverse primer mix, and 10.5 mL nuclease free water) were cycled
at 95uC for 10 minutes, followed by 40 cycles consisting of 95uC
for 15 seconds and 60uC for 1 minute. Melt-curve analysis was
performed at the end of each qPCR experiment to verify single
amplicons, and the correct length of PCR products was verified by
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follows: CYP1A1, Forward, 59-CTT CAC CCT CAT CAG TAA
TGG TC-39, Reverse 59-AGG CTG GGT CAG AGG CAA T-
39; CDKN1A, Forward, 59- TGT CCG TCA GAA CCC ATG C -
39, Reverse 59- AAA GTC GAA GTT CCA TCG CTC -39; C-
Myc, Forward, 59- GGC TCC TGG CAA AAG GTC A-39,
Reverse 59- AGT TGT GCT GAT GTG TGG AGA-39; GAPDH
Forward, 59-ACC TTT GAC GCT GGG GCT GG-39, Reverse,
59-CTC TCT TCC TCT TGT GCT CTT CGT GG -39.
Reactions were performed in triplicate, and data was analyzed by
the DDCt method.
Real-time Cell Analysis
Real time analysis of cellular proliferation was performed using
a Real-Time Cell Analyzer (RTCA) DP instrument with E-plate
16 assay platforms (Roche, USA). Measurement and basic analysis
of real time analysis data was performed essentially according to
the manufactures recommended protocol. Briefly, A375-pTRIPZ-
shAhR cells that had never been exposed to doxycycline (AhR
proficient) or had been induced for $72 hours with 2 mg/mL
doxycycline (AhR knockdown) were seeded at a density of 2000
cells/well in a final volume of 200 mL with or without DOX as
above. Prior to addition of 100 mL of media containing cells, the
instrument was blanked with 100 mL of media. After approxi-
mately 18 hours, or when the cells appeared to be entering an
exponential growth phase, compounds were added via addition of
20 mL of an 11X stock. DOX was added to the appropriate wells
after 48 hours to maintain knockdown. In all experiments, water,
the solvent for doxycycline, was added to no-DOX cells as
a control.
Cellular Viability Assay
Cell viability assays were performed as described previously,
with modification. [22] Viability was determined using the
CellTiter Glo Luminescent Cell Viability Assay (Promega,
Madison, WI). Luminescence readings were recorded as pre-
viously described. [18,27] Verification of non-confluent cell status
in experiments (i.e. vehicle control wells) was determined by visual
assessment (phase contrast microscopy).
Electrophoretic Mobility Shift Assay (EMSA)
To study the ligand-induced AhR binding to DNA, EMSA was
performed as described previously. [29] Briefly, whole cell lysate
(16 mg of protein) from human melanoma A375 cells were pre-
incubated with A771726 or DMSO for 30 minutes at RT, and
incubated with leflunomide or TCDD for 2 hours at RT. The
liganded lysates were incubated with
32P-labeled double stranded
oligonucleotide containing mouse Cyp1a1 xenobiotic responsive
element (XRE) for 15 minutes at RT, which was separated by
native gel electrophoresis. The dried gel was exposed to the
Phospho Imager to visualize the signal.
Uridine Rescue of DHODH Inhibition
Fresh uridine stock solutions were prepared daily to a concen-
tration of 100 mM in 10% DMEM. Preparations were filter
sterilized with a 0.22 mm filter before use in cell culture.
CFSE Staining
For CFSE analysis, cells were harvested, washed with PBS, and
resuspended at a density of 1610
7 cells/ml. CFSE was then added
to the suspension to a final concentration of 1 uM and incubated
for 8 minutes at RT. A 25% volume equivalent of FBS or DMEM
with 10%FBS was added to stop the labeling. Cells were washed
2X with PBS and counted for plating. Cells were removed prior to
and after staining to verify CFSE incorporation. Post treatment
cells were harvested and washed twice in PBS and resuspended in
100 uL BD cytofix and incubated on ice for 1 hour. Cell were then
washed twice with PBS and stored at 4uC until analysis. The entire
procedure was carried out in dark. Flow cytometry analysis was
performed as described previously. [28]
Cancer Cell Line Encyclopedia
Gene expression data for AhR and DHODH across a panel of
967 cancer cell lines were downloaded from the Cancer Cell Line
Encyclopedia (CCLE). [26] The mutational status of BRAF
(V600E) in MDA-MB-435S cells was also determined using the
CCLE.
Statistical Analysis
Data were analyzed by one-way ANOVA with either Tukey’s or
Bonferroni’s post-test using Prism software (Version 5.0, Graph-
pad, La Jolla, CA). Values of P,0.05 were considered statistically
significant.
Results
AhR Signaling is Intact in A375 Melanoma Cells
In the present study, we hypothesized that the effects of
leflunomide in A375 melanoma cells are mediated by a previously
unappreciated activation of the AhR. We first confirmed the
expression of AhR in A375 melanoma cells by Western blot. A375
cells expressed a significant level of AhR; Mouse Hepa1 cells were
used as positive control for AhR expression (Figure 1A). To
determine whether AhR signaling is functional in A375 cells, we
next tested whether the AhR ligands could upregulate expression
the AhR target gene CYP1A1 in a time and dose-dependent
manner (Figure 1B). At 6, 12, and 24 hours, treatment of A375
cells with 100 mM leflunomide resulted in a 7.160.2, 8.260.9,
and 13.961.1 fold increase in CYP1A1 expression relative to
matched vehicle controls (p,0.0001 for all timepoints, n=3); A
dose dependent effect was also apparent at each timepoint.
Treatment with 1 nM TCDD for 24 hours also significantly
increased CYP1A1 expression in A375 melanoma cells (data not
shown). Activation of the AhR by a ligand leads to its nuclear
translocation from the cytosol. Treatment of A375 cells with
leflunomide resulted in strong nuclear localization of AhR
compared to vehicle treated cells (Figure 1C). In addition, we
evaluated the expression of AhR across 967 cancer cell lines using
the recently developed cancer cell line encyclopedia. [26] We
found that AhR is expressed across a wide spectrum of tumor
lineage types including those from breast, liver, lung, prostate,
stomach, and colorectal cancers. Skin-derived cancer cells
exhibited relatively high levels of AhR expression comparable to
that of liver cancer cells (Figure 1D). Among skin-derived cancer
cells, A375 melanoma cells and MDA-MB-435S cells, [30] which
were used in this study, expressed high levels of AhR (figure 1E).
Our observation of AhR expression and downstream signaling in
melanoma cells is supported by a previous study performed in
human melanocytes. [24] Taken together, these data indicate that
AhR is highly expressed in transformed melanoma cells and that
AhR signaling is activated following treatment with leflunomide in
A375 melanoma cells.
Leflunomide-mediated Inhibition of A375 Cellular
Proliferation is Dependent on AhR Expression
We first confirmed that leflunomide inhibits the proliferation of
A375 cells as previously demonstrated. [22] At concentrations of
AhR Regulates Leflunomide’s Effects in Melanoma
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cells by approximately 60% and 20% respectively, relative to
vehicle (data not shown). We next determined whether the anti-
proliferative effects of leflunomide in A375 cells require AhR
expression. To this end, we generated an A375 cell line in which
AhR expression was controlled by a doxycycline (DOX) inducible
shRNA (pTRIPZ-shAhR). Suppression of AhR protein abundance
in pTRIPZ-shAhR expressing A375 cells after 72 hours of
treatment with 2 mg/mL DOX was confirmed by Western blot
(Figure 2A). In addition, a red fluorescent Protein (RFP) reporter
also under the regulation of DOX in the same vector was potently
induced by DOX as determined by flow cytometry analysis,
(Figure 2B) indicating stable, uniform expression of the pTRIPZ-
shAhR insert in this cell line. To verify that the AhR knockdown
was functionally relevant with respect to target gene activation, we
next treated A375 cells expressing pTRIPZ-shAhR cells with
leflunomide (100 mM) in the absence or presence of DOX (normal
AhR expression and AhR knockdown, respectively) and evaluated
the effect of decreased AhR expression on CYP1A1 induction.
Consistent with the data in Figure 1B, expression of CYP1A1 was
strongly induced by leflunomide in cells expressing AhR, but was
significantly attenuated upon AhR knockdown (P,0.001 Leflu-
nomide –DOX vs Leflunomide +DOX, n=3) (Figures 2A and
2C). A375 cells with normal or reduced expression of AhR did not
display apparent differences in morphology, nor did they display
noticeably different profiles of growth in culture (Figure 2D).
Having verified the ability to induce knockdown of AhR in
A375 cells and demonstrating that suppression of AhR expression
abolishes AhR-mediated induction of CYP1A1 by leflunomide, we
next evaluated the effect of AhR knockdown on proliferation of
A375 cells treated with leflunomide. First, A375-pTRIPZ-shAhR
cells were treated with 100, 50, and 25 mM leflunomide with or
without DOX, and cell viability was determined after 96 hours
(Figure 3A). The percent of viable A375 cells exposed to 100, 50,
and 25 mM leflunomide relative to vehicle treated cells were
15.260.8%, 23.263.2%, and 42.062.5%, whereas suppression of
Figure 1. Intact AhR signaling in A375 melanoma cells. (A) Western blot comparing relative abundance of AhR in human A375 melanoma cells
and mouse Hepa1c1c7 hepatoma cells; h and m indicate the position of human and mouse AhR isoforms, respectively. GAPDH is shown as an equal
loading control. (B) qPCR analysis of CYP1A1 induction in A375 melanoma cells after 6, 12, and 24 hours of treatment with vehicle (0.1% v/v DMSO), or
leflunomide at the indicated concentrations. Data are the mean 6 SD of 3 independent experiments *** P,0.0001, ** P,0.001, * P,0.01. (C)
Leflunomide-induces nuclear localization of the AhR. A375 cells were treated for 4 hours with DMSO or leflunomide (100 mM) and AhR localization
was visualized. (D) AhR mRNA expression profile (Log2, RMA) of 967 cancer cell lines. Expression profiles of AhR in melanoma cells are compared with
liver cancer cells, which have high AhR expression. (E) Box and whisker plots (error bars: min/max expression) of cancer cell line encyclopedia AhR
mRNA data for non-melanoma and melanoma extracted from (D). Expression of AhR in melanoma cells vs all other cancer cell types are indicated. The
AhR mRNA abundance of the two cell lines used in the study, MDA-MB-435 and A375, are depicted by dashed lines.
doi:10.1371/journal.pone.0040926.g001
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64.2610.7%, and 90.561.9%, respectively (Mean 6 SD,
p,0.0001 for all treatments). Phase contrast microscopy also
revealed a noticeable difference between A375 cells treated with
leflunomide with normal or reduced AhR protein levels
(Figure 3B).
To further evaluate the AhR-dependent anti-melanoma effects
of leflunomide, we next examined the role of AhR in mediating
the anti-proliferative effects of leflunomide using xCELLigence
system, which monitors the combined parameters of cellular
proliferation and morphology in real-time through an electrical-
impedance based measurement calculated as a cell index. [31]
A375 cells with normal or reduced AhR expression were treated
with leflunomide at concentrations of 100, 50, 25 mM and
proliferation was compared relative to a vehicle control. Consis-
tent with the results of our endpoint analysis of A375 cell viability,
A375 cells with reduced AhR expression had much higher cell
index at all time points compared to A375 cells expressing AhR
Figure 2. Inducible knockdown of AhR in A375 melanoma cells. (A) Western blot of the A375-pTRIPZ-shAhR cell line in the absence (-) or
presence (+)o f2mg/mL doxycycline (DOX) for 72 hours. GAPDH is shown as an equal loading control. (B) Flow cytometry analysis of red fluorescent
protein (RFP) reporter with and without DOX in A375-pTRIPZ-shAhR cells. (C) qPCR analysis of CYP1A1 induction in A375-pTRIPZ-shAhR cells after 24
hours of treatment with vehicle or leflunomide in the absence or presence of DOX. Data are the mean 6 SD, *** P,0.0001 NS: Non-significant, n=3.
(D) Real time cellular analysis of A375-pTRIPZ-shAhR proliferation with or without AhR knockdown. Data are the mean 6 SD of two biological
replicates, and are representative of at least three similar experiments.
doi:10.1371/journal.pone.0040926.g002
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end of the assay by ANOVA, and significant differences in cell
indices were observed for treatments of 100 and 50 mM
leflunomide with or without AhR (Figure 3D, p,0.001).
In addition to xCelligence monitoring, we also utilized
carboxyfluorescein diacetate succinimidyl ester (CFSE) staining
to track proliferating A375-pTRIPZ-shAhR cells by flow cyto-
metry. Dilution of CFSE fluorescence in vehicle treated cells was
readily apparent at 72 hours compared to cells stained at the start
of the treatments (‘day 0’) (Figure 4, top panels). After 72 hours,
a dose-dependent increase in CFSE fluorescence intensity, which
is indicative of fewer cellular divisions, was observed in
leflunomide treated samples. Consistent with our viability and
real-time cell monitoring, this effect was significantly decreased in
DOX-treated cells, indicating that suppression of AhR expression
led to more cellular divisions compared to cells expressing normal
levels of AhR, after leflunomide treatment. Specifically, the
difference in CFSE fluorescence intensity between vehicle treated
cells and cells treated with 100, 50, and 20 mM leflunomide for 72
hours was 65%, 51%, and 47%, respectively. However, suppres-
sion of AhR expression strongly shifted CFSE fluorescence
intensity towards the vehicle control, such that treatment with
100, 50, and 20 mM leflunomide under the same conditions
produced a much smaller difference in CFSE fluorescence relative
to vehicle controls (40%, 31%, and 25%, respectively; Figure 4).
Interestingly, no difference in CFSE fluorescence was observed
when cells were treated with 1 nM TCDD at either time-point,
regardless of AhR expression. Taken together, our analysis of the
effects of leflunomide in A375 cells revealed that AhR knockdown
conferred a significant resistance to the anti-proliferative effects of
Figure 3. Leflunomide mediated inhibition of A375 melanoma cells is significantly dependent upon AhR expression. (A) Viability of
A375-pTRIPZ-shAhR melanoma cells treated with the indicated doses of leflunomide in the absence (AhR-expressing) or presence (AhR-knockdown)
of 2 mg/mL doxycycline. Results are the mean 6 SD of three independent experiments. N=6; * P,0.0001 compared to respective dose of
leflunomide in the absence of doxycycline. (B) Phase-contrast microscopy images of A375-pTRIPZ-shAhR cells treated with either vehicle or
leflunomide (100 mM) for 72 hours in the absence or presence of doxycycline. (C) Real time cellular analysis of A375-pTRIPZ-shAhR proliferation with
or without AhR knockdown in the presence of vehicle (0.1% v/v DMSO) or leflunomide at concentrations of 100, 50, or 25 mM. Data are the mean of
two biological replicates and are representative of two independent experiments. (D) Cell index values at the end of the real-time analysis period (1)
were evaluated by ANOVA.
doi:10.1371/journal.pone.0040926.g003
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pTRIPZ-shAhR cells with or without DOX induced-AhR knockdown were stained with CFSE and treated with vehicle (DMSO 0.1% v/v), 1 nM TCDD, or
leflunomide at 20, 50, and 100 mM for 72 hours followed by flow cytometry. Vehicle treated cells (top panels, green histograms) exhibited decreased
CFSE fluorescence intensity compared to cells before the start of treatments (‘time 0’) (solid histograms), reflecting dilution of CFSE in vehicle-treated
cells and reflecting cell division. Numbers indicate the percent difference between vehicle (green) and treatment (Red -Dox; Orange +Dox) within
histogram plots.
doi:10.1371/journal.pone.0040926.g004
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strongly indicating that the AhR regulates the anti-proliferative
effects of leflunomide in melanoma cells.
A771726 Inhibition of A375 Melanoma Cells is
Independent of AhR
We previously reported that metabolic conversion of lefluno-
mide to A771726 abrogates its ability to activate the AhR in hepa1
hepatoma cells. [18] To confirm and extend this finding to A375
melanoma cells, we performed electrophoretic mobility shift assays
(EMSA) using whole cell extracts of A375 cells and XRE sequence
containing DNA probes. Incubation of A375 cell extracts with
leflunomide resulted in a strong XRE-band compared with
DMSO treatment (Figure 5A, lane 3 vs lanes 4–6), whereas
A771726 failed to generate such a signal (Figure 5, lanes 4–9).
Specificity of signal was confirmed by the addition of non-labeled
(cold) wildtype (wt) XRE-probe (Figure 5A, lane 2), which
specifically inhibited the leflunomide-induced XRE gel shift. A
cold mutant XRE probe had no effect on leflunomide-induced gel
shift (Figure 5A, lane 1). In addition, pre-incubation of A375 cell
extracts with three different concentrations of A771726 did not
antagonize the ability of leflunomide-induced AhR DNA binding.
Given that the anti-proliferative effects of leflunomide are
dependent upon the AhR, the inability of A77176 to activate
the AhR suggests that AhR is not involved in the growth inhibition
of A375 cells by A771726. Consistent with this prediction, A375
cells expressing pTRIPZ-shAhR with or without DOX did not
exhibit any differences in proliferation upon treatment with
various doses of A771726 ranging from 25 to 100 mM (Figure 5B).
Thus, while A771726 is also able to inhibit A375 melanoma cells,
these effects are independent of the AhR expression.
The Anti-proliferative Effects of Leflunomide in A375
Melanoma Cells are only Partially DHODH-Dependent
Dihydroorotate Dehydrogenase (DHODH) is an essential
enzyme in the de novo pyrimidine biosynthesis pathway, and
inhibition of DHODH is mediated by the active metabolite of
leflunomide, A771726. Through this mechanism of action,
leflunomide is currently used in the clinic to inhibit proliferation
of T-cells to produce an immunosuppressive effect useful for the
treatment of autoimmune diseases such as rheumatoid arthritis.
Importantly, the DHODH inhibitory effects of leflunomide (after
its conversion to A771726) are completely rescued by supplemen-
tation with exogenous uridine, which can be salvaged to uridine
monophosphate (UMP) by uridine kinase. [20,32–34] Further-
more, inhibition of DHODH was proposed by White et al as
a potential anti-melanoma therapy. [22] To investigate the degree
to which DHODH inhibition by leflunomide contributes to the
anti-proliferative effects in melanoma cells, we performed uridine
rescue experiments in A375 and MDA-MB-435S melanoma cells
[30,35], both of which express abundant levels of AhR (Figure 1E
and 6A).
We first performed a uridine dose response rescue in A375 and
MDA-MB-MB435S cells to identify the minimum effective
concentration of uridine that rescues cells from the anti-pro-
liferative effects of leflunomide at 100 mM. Compared with
vehicle-treated A375 cells without exogenous uridine
(99.964.9%), concentrations of uridine ranging from 10 mMt o
10 mM added at the beginning of the assay had little to no effect
on A375 viability (100.3610.1% to 98.267.2%, respectively)
(Figure 6B). Consistent with our previous observations, treatment
of A375 cells with 100 mM leflunomide for 96 hours significantly
reduced viability; however, while supplementation with uridine
did improve viability, the effect was only partial and reached
a plateau with uridine concentrations higher than 100 mM. The
viability of A375 cells treated with leflunomide and supplemented
with uridine at 10 mM, 100 mM, 1 mM, and 10 mM was
37.061.7%, 49.865.5%, 50.662.8%, and 50.364.2%, respec-
tively (Figure 6B). Thus, the maximum rescue of viability of cells
by uridine supplementation treated with 100 mM leflunomide was
approximately 18%, suggesting DHODH inhibition is only
partially responsible for the anti-proliferative effects of leflunomide
and other mechanism(s) contributing to the effects of leflunomide.
This assay was repeated in MDA-MB-435S cells, which largely
recapitulated the results from A375 cells, with the notable
exception that 10 mM uridine dramatically reduced viability of
vehicle and TCDD treated cells (Figure 6C). Based on these
results, a concentration of 1 mM uridine was chosen for use in
additional uridine rescue experiments.
To confirm that the partial rescue of cell viability was not due to
degradation of uridine during the assay, an additional experiment
was performed whereby viability of cells treated with leflunomide
or A771726 at 100 mM for 96 hours was evaluated after a single
addition of uridine at the beginning of the assay, or by daily
replacement of media with freshly prepared uridine and
compounds. Consistent with our observation above, cell viability
after treatment with leflunomide or A771726 again was rescued to
a similar, albeit incomplete, degree following either single or daily
supplementation with uridine in A375 and MDA-MB-435S cells
(Figures 6D and 6E, respectively). Interestingly, while A375 cells
did respond to uridine in terms of a partial increase in viability, no
significant increase in viability was observed in MDA-MB-435S
cells. We next examined a range of leflunomide and A771726
concentrations (100 mM to 6.25 mM) in the absence or presence of
1 mM uridine. Consistent with the above findings, uridine only
partially rescued A375 viability even at lower doses of leflunomide
and A771726 (Figure 6F). Likewise, MDA-MB-435S cells were
largely unresponsive to uridine supplementation (Figure 6G),
strongly supporting a DHODH-independent anti-melanoma
activity of leflunomide and A771726.
Expression of P21
cip1 is Increased by Leflunomide in A375
Melanoma Cells
Having found that uridine only partially rescues melanoma cells
from the anti-proliferative effects of leflunomide, we next
evaluated potential downstream targets of leflunomide. To this
end, A375 cells were treated with either vehicle, 1 nM TCDD,
and leflunomide at 50 mM and 100 mM for 48 and 72 hours, after
which protein lysates were then collected and analyzed by Western
blot to evaluate the effect of leflunomide on expression of several
proteins that are known to regulate cell cycle progression, namely,
p21
cip1, p27
kip1, CDK4, CDK6, Cyclin D1, and Cyclin D3
(Figure 7A). While the expression profiles of the majority of these
proteins from this panel were consistent with the GAPDH loading
control, a significant increase in p21 expression by leflunomide at
50 and 100 mM was observed (Figure 7A). We also confirmed
increase in p21 mRNA expression by leflunomide using qPCR
(Figure 7B). Interestingly, p21 has been described previously as
a downstream target gene of AhR activation by 3-methylcholan-
threne, an AhR ligand, [16] but not TCDD. [36]
Expression of c-Myc is not altered by Leflunomide in
A375 Melanoma Cells
Lastly, we evaluated the effect of leflunomide on c-Myc
expression, which was described as a molecular target of DHODH
inhibition by leflunomide due to decreased transcriptional
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AhR. [37] We did not observe any appreciable changes in c-Myc
expression by leflunomide at either the mRNA or protein level
(Figures 8A-B).
Discussion
In the present study, we identified an AhR-dependent
inhibition of proliferation of A375 melanoma cells by the
clinically-used drug leflunomide (Figure 3), which has been
reported previously to activate the AhR. [17,18,38] Our results
confirm the clinical potential of leflunomide in treating
melanoma, and offer insight into its mechanism of action.
Inhibition of DHODH was proposed as the mechanism of
action for the anti-proliferative effects of leflunomide in
melanoma. [22] Knockdown of DHODH expression was shown
to inhibit cellular proliferation, which provides only corollary
evidence for the effects of leflunomide in melanoma cells, and
thus does not provide direct evidence that leflunomide functions
by a DHODH-dependent mechanism. [22] To directly test
whether DHODH is involved in the anti-proliferative effects of
leflunomide, we performed uridine rescue experiments (Figure 6).
Our results demonstrated that uridine supplementation only
partially rescued A375 cells from the anti-proliferative effects of
not only leflunomide, but also A771726 (Figures 4,5,6), strongly
suggesting additional mechanism(s) of action of leflunomide in
melanoma. In support of this observation, the MDA-MB-435S
cell line, which shares the same BRAF
V600E mutation as A375
cells, failed to exhibit any significant rescue by uridine with
respect to the anti-proliferative effects of leflunomide (Figure 6).
Our observation of a DHODH-independent mechanism of
leflunomide is consistent with the different ranges of leflunomide
concentrations necessary to achieve inhibition of A375 cellular
proliferation and those needed for DHODH inhibition. [20]
Likewise, complete rescue of the anti-proliferative effects of
A771726 have been demonstrated by uridine previously in non-
lymphoid cells including osteosarcoma, rat liver, and smooth
muscle cells in vitro. [33,39] Thus, our observation of incomplete
rescue of melanoma cell proliferation by uridine strongly suggests
additional mechanisms of action of leflunomide and A771726.
Additional molecular targets for A771726 have been proposed,
including receptor tyrosine kinase inhibition, which may explain
why leflunomide, but not A771726, exhibited AhR-dependent
anti-proliferative effects.
With respect to the anti-proliferative potential of leflunomide,
our findings are largely consistent with those of White et al.,
confirming its anti-melanoma activity while providing further
insight into its mechanism of action. Our results demonstrate
that AhR is the molecular target of leflunomide and it is
Figure 5. The anti-proliferative effects of A771726 are AhR independent. (A) Leflunomide, but not A771726 induce DNA-binding of the AhR
and A771726 does not antagonize leflunomide-induced DNA binding of the AhR. Whole cell extracts (16 mg of protein) from human melanoma A375
cells were pre-incubated with or without A771726 or DMSO for 30 minutes at room temperature (RT), followed by incubation with leflunomide at the
indicated concentrations for 2 hours at RT. The resulting lysates were incubated with
32P-labeled double stranded oligonucleotide containing mouse
CYP1A1 xenobiotic responsive element (XRE) for 15 minutes at RT, which was separated by native gel electrophoresis. The dried gel was exposed to
Phosphor Imager to visualize the signal. As a specificity control, 10 ng unlabeled (cold) wild type (wtXRE) or mutant (mtXRE) probes were incubated
with the lysates treated with leflunomide for 15 minutes at RT, followed by incubation with
32P-labeled probe. (B) Inhibition of A375 melanoma cell
proliferation by A771726 is independent of AhR expression. Viability of A375-pTRIPZ-shAhR cells with or without doxycycline was measured 96 hours
after treatment with the indicated concentrations of A771726. NS, not significant with respect to the indicated comparison; * P,0.05, Data are the
mean 6 SD of three independent experiments.
doi:10.1371/journal.pone.0040926.g005
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and 4). Whether AhR activates a distinct pathway to mediate
leflunomide’s anti-proliferative effects or controls conversion of
leflunomide into its active metabolite remains to be established.
Leflunomide is thought to be rapidly converted to A771726 in
the gut and plasma; however, the extent to which first pass
metabolism also plays a role in this process is not fully
understood. We previously reported that A771726 failed to
activate AhR-mediated gene transcription or promote nuclear
translocation of the AhR. [18] Consistent with this observation,
A771726 did not antagonize leflunomide-induced AhR DNA
binding (Figure 5). Thus, our data strongly suggest that the
effects of A771726 in melanoma are functionally independent of
the AhR. We previously reported that the ring-opening event
involved in the conversion of leflunomide to A771726 generates
unfavorable docking conditions for A771726 to bind to the
AhR. [16] With respect to potential molecular targets of
leflunomide in melanoma, we did not observe any changes of c-
MYC mRNA or protein expression by leflunomide (Figure 8);
however, we did observe significantly increased levels of p21
Cip1
by leflunomide (Figure 7).
Taken together, our results support the feasibility of using
leflunomide to treat melanoma. For the treatment of rheumatoid
arthritis, leflunomide is currently administered orally with
a loading dose of 100 mg tablets followed by daily ingestion of
10 or 20 mg tablets. A771726 is detected at significant concentra-
tions following oral administration, whereas detection of lefluno-
mide in plasma is significantly lower (AravaH product insert).
White et al. were able to successfully use intraperitoneal injections
of leflunomide (7.5 mg/kg) to inhibit the growth of A375
xenografts in nude mice (Supplemental Figure 16 of reference
[22]). Clinical administration of leflunomide to treat melanoma in
humans will likely require alternative routes of administration
other than the oral route to achieve effective plasma concentra-
tions of leflunomide. Nevertheless, the recent study by White et al.
allowed us to identify an overlooked AhR-dependent anti-cancer
effect of leflunomide, and our results support the feasibility of the
Figure 6. Supplementation with exogenous uridine only partially rescues melanoma cells from the anti-proliferative effects of
leflunomide. (A) Relative AhR expression in A375 and MDA-MB-435S melanoma cell lines was analyzed by Western blot; GAPDH was used as
a loading control. (B-C) Viability of A375 (B) and MDA-MB-435S (C) cells treated with either vehicle (0.1% v/v DMSO), TCDD (1 nM), or leflunomide
(100 mM) supplemented with a range of concentrations of uridine. (D-E) Viability of A375 (D) and MDA-MB-435S (E) cells supplemented with or
without exogenous uridine (1 mM) treated with either vehicle (0.1% v/v DMSO), TCDD (1 nM), A771726 (100 mM) and leflunomide (100 mM). Cells
were treated either once (single treatment) with the indicated compounds, or exposed to freshly prepared stock solutions every 24 hours (daily
treatment) until the end of the experiment. NS, not significant with respect to the indicated comparison; #,P ,0.05 with respect to the indicated
comparison; *, P,0.0001 with respect to the corresponding vehicle control, relative to the presence or absence or uridine and treatment as indicated.
Data are the mean 6 SEM of three independent determinations. (F–G) Leflunomide and A771726 dose-dependent effects in A375 (F) and MDA-MB-
435S (G) of cells treated with 1 mM uridine or vehicle. Data are the mean 6 SD of three independent experiments.
doi:10.1371/journal.pone.0040926.g006
Figure 7. Leflunomide induces expression of p21
Cip1 in A375 melanoma cells. (A) Protein lysates from A375 cells treated with Vehicle,
TCDD, or leflunomide at 100 and 50 mM for 48 and 72 hours were analyzed by Western blot for a panel of cell-cycle regulatory proteins comprising
p21, p27, CDK4, CDK6, Cyclin D1, and Cyclin D3. GAPDH was used as a loading control. (B) Expression of p21 mRNA in A375 cells treated with vehicle
or leflunomide at 100 and 50 mM was analyzed by qPCR. Data are the mean 6 SD, n=3, # P,0.05, *** P,0.0001.
doi:10.1371/journal.pone.0040926.g007
AhR Regulates Leflunomide’s Effects in Melanoma
PLoS ONE | www.plosone.org 11 July 2012 | Volume 7 | Issue 7 | e40926clinical application of leflunomide in melanoma and provide
insight into leflunomide’s anti-proliferative effects.
Lastly, we evaluated AhR expression among 967 cancer cell
lines using the newly developed Cancer Cell Line Encyclopedia.
[26] As AhR is highly expressed in several cancer types
(Figure 1D), tumor suppressive actions of the AhR may be
exploited to develop AhR-based therapeutics for several cancers
including breast, liver, lung, prostate, stomach, and colorectal
cancers.
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